Achillion Pharmaceuticals (ACHN) Upgraded to Hold at BidaskClub

BidaskClub upgraded shares of Achillion Pharmaceuticals (NASDAQ:ACHN) from a sell rating to a hold rating in a research note published on Tuesday morning.

ACHN has been the topic of several other research reports. Zacks Investment Research raised Achillion Pharmaceuticals from a hold rating to a buy rating and set a $4.50 target price on the stock in a research note on Monday, November 6th. B. Riley began coverage on Achillion Pharmaceuticals in a research note on Thursday, February 8th. They set a neutral rating and a $3.50 target price on the stock. Finally, Leerink Swann reissued a buy rating and set a $5.00 target price on shares of Achillion Pharmaceuticals in a research note on Monday, December 11th. One research analyst has rated the stock with a sell rating, six have given a hold rating and three have assigned a buy rating to the stock. Achillion Pharmaceuticals currently has an average rating of Hold and an average price target of $4.89.

Shares of Achillion Pharmaceuticals (NASDAQ ACHN) opened at $3.20 on Tuesday. The stock has a market capitalization of $441.14, a P/E ratio of -6.53 and a beta of 1.32. Achillion Pharmaceuticals has a 12 month low of $2.58 and a 12 month high of $5.66.

In related news, major shareholder & Johnson Johnson sold 18,367,346 shares of Achillion Pharmaceuticals stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $2.75, for a total transaction of $50,510,201.50. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 7.24% of the stock is currently owned by company insiders.

A number of large investors have recently added to or reduced their stakes in ACHN. Schwab Charles Investment Management Inc. increased its stake in Achillion Pharmaceuticals by 0.6% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 457,341 shares of the biopharmaceutical company’s stock worth $2,100,000 after acquiring an additional 2,850 shares during the last quarter. Wells Fargo & Company MN increased its stake in Achillion Pharmaceuticals by 1.8% in the 2nd quarter. Wells Fargo & Company MN now owns 219,647 shares of the biopharmaceutical company’s stock worth $1,009,000 after acquiring an additional 3,827 shares during the last quarter. TIAA CREF Investment Management LLC increased its stake in Achillion Pharmaceuticals by 5.2% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 428,933 shares of the biopharmaceutical company’s stock worth $1,969,000 after acquiring an additional 21,183 shares during the last quarter. Nationwide Fund Advisors increased its stake in Achillion Pharmaceuticals by 15.2% in the 2nd quarter. Nationwide Fund Advisors now owns 93,443 shares of the biopharmaceutical company’s stock worth $429,000 after acquiring an additional 12,303 shares during the last quarter. Finally, UBS Asset Management Americas Inc. increased its stake in Achillion Pharmaceuticals by 18.6% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 63,669 shares of the biopharmaceutical company’s stock worth $292,000 after acquiring an additional 10,000 shares during the last quarter. 76.81% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/17/achillion-pharmaceuticals-achn-upgraded-to-hold-at-bidaskclub.html.

Achillion Pharmaceuticals Company Profile

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Analyst Recommendations for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply